KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Other Non-Current Assets (2016 - 2025)

Neogenomics (NEO) has disclosed Other Non-Current Assets for 15 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 59.6% year-over-year to $9.4 million, compared with a TTM value of $9.4 million through Dec 2025, up 59.6%, and an annual FY2025 reading of $9.4 million, up 59.6% over the prior year.
  • Other Non-Current Assets was $9.4 million for Q4 2025 at Neogenomics, up from $7.1 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.4 million in Q4 2025 and bottomed at $3.2 million in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $6.0 million, with a median of $5.5 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets tumbled 90.12% in 2021, then skyrocketed 59.6% in 2025.
  • Year by year, Other Non-Current Assets stood at $7.2 million in 2021, then fell by 28.72% to $5.1 million in 2022, then fell by 7.18% to $4.7 million in 2023, then rose by 24.12% to $5.9 million in 2024, then surged by 59.6% to $9.4 million in 2025.
  • Business Quant data shows Other Non-Current Assets for NEO at $9.4 million in Q4 2025, $7.1 million in Q2 2025, and $5.9 million in Q4 2024.